- |||||||||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Dec 8, 2013 P2, N=68, Recruiting, Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- |||||||||| Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: SOLTI-Opti-HER: Study of Neoadjuvant Myocet (clinicaltrials.gov) - Nov 11, 2013 P2, N=83, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy, Metastases: A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer (clinicaltrials.gov) - Oct 27, 2013 P1, N=99, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Jul 29, 2013 P2, N=68, Recruiting,
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Metastases: A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 28, 2013 P1, N=107, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Combination therapy, Metastases: PERNETTA: Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (clinicaltrials.gov) - Jul 22, 2013 P2, N=208, Recruiting, Not yet recruiting --> Recruiting Initiation date: Apr 2013 --> Jul 2013
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: NSABP Biospecimen Discovery Project (clinicaltrials.gov) - Jul 17, 2013 P=N/A, N=50, Recruiting, Initiation date: Apr 2013 --> Jul 2013 Not yet recruiting --> Recruiting
- |||||||||| Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date: SOLTI-Opti-HER: Study of Neoadjuvant Myocet (clinicaltrials.gov) - Jul 2, 2013 P2, N=83, Active, not recruiting, Not yet recruiting --> Recruiting Initiation date: Nov 2012 --> Jun 2013
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Metastases: A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 25, 2013 P1, N=107, Completed, Recruiting --> Active, not recruiting N=74 --> 107
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: PERNETTA: Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (clinicaltrials.gov) - Apr 14, 2013 P2, N=208, Recruiting, N=74 --> 107 Not yet recruiting --> Recruiting
- |||||||||| Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: SOLTI-Opti-HER: Study of Neoadjuvant Myocet (clinicaltrials.gov) - Aug 16, 2012 P2, N=83, Active, not recruiting,
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Metastases: A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) (clinicaltrials.gov) - May 31, 2012 P3, N=1095, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
|